European Regulatory Round-Up: New Faces; Revised Guidances; More Cost Controls
Executive Summary
A new chairman will take the helm of Germany's G-BA panel at a pivotal time for AMNOG implementation; the European Medicines Agency issues guidances in oncology drug development and genotoxicity; more regulatory updates.
You may also be interested in...
Pfizer Turns To Ventana To Expand Companion Dx Options For Xalkori
Pfizer has partnered with Ventana to develop a second companion diagnostic to test for ALK gene mutations to identify patients who could benefit from treatment with Xalkori.
Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta
Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working
European Austerity Drama May Likely Spur The Pace But Not Change The Strategic Plot Line For Pharma
Price cuts and austerity measures made 2011 a bleak year for European pharma. These dynamics are more severe but not new, and likely will accelerate firms’ existing geographic expansion and market access strategies.